Gabrielle DeBartolomeo is the clinical trial scientist at Alkeus Pharmaceuticals, a Boston-based biotech focused on developing treatments for rare and common forms of currently untreatable blindness including age-related macular degeneration and Stargardt disease. Wearing multiple hats in the company, she is responsible for clinical operations activities and coordinates operational and regulatory activities with private practice and academic sites, in addition to leading patient outreach and support. Through this role, she has witnessed firsthand the multidimensional impact of COVID-19 on clinical trials.